Finvest
VEEV Health Care Software · Vertical SaaS · Life sciences · CRM migration · Thesis updated June 12, 2026

R&D growth offsets a risky CRM handoff

01 Running thesis

Strong core, tense handoff

Veeva is a focused cloud software company for life sciences. That focus is its edge. Drug companies and medical device makers use Veeva in regulated work, where changing systems can be costly, slow, and risky.

The growth story is moving toward R&D and Quality Solutions. That segment reached 55% of total revenue in fiscal 2026, up from 53% the year before. It stayed at 55% of total revenue in Q1 FY27. This mix shift supports the bull case because R&D and quality tools can grow even if the older commercial side has a harder year.

The hard part is the CRM handoff. Veeva's legacy CRM product was built on Salesforce's platform. Veeva is moving customers to Vault CRM, its own platform, and the Salesforce agreement is not being renewed after 2025, with support ending in 2030. That could improve control, margins, and product speed over time.

The bear case is no longer just a theory. Veeva disclosed that some customers have chosen competitors, and Salesforce has announced that certain large Veeva CRM customers have committed to its CRM products. Finn's view is balanced: Veeva has a strong niche and good financial health, but investors need proof that R&D growth and Vault CRM wins can offset CRM churn.

Jun 2026→The Q1 FY27 filing kept the revenue mix steady at 45% Commercial Solutions and 55% R&D and Quality Solutions. The Salesforce and Vault CRM migration risks were repeated without a material change.
Mar 2026→The fiscal 2026 10-K strengthened both sides of the thesis. R&D and Quality Solutions rose to 55% of total revenue, but Veeva also gave clearer disclosure that some CRM customers intend to move to Salesforce.
Nov 2025▲The Q3 FY26 filing showed the mix shift toward R&D Solutions continuing, with that area at 55% of total revenue for the nine-month period. R&D subscription revenue growth outpaced Commercial Solutions growth over that period.
Aug 2025▲The Q2 FY26 filing confirmed that R&D Solutions reached 55% of total revenue for the first six months of the fiscal year. No new material risk changed the core view.
Jun 2025→The initial thesis framed Veeva as a focused life sciences software company with sticky products. It also named the move from legacy Veeva CRM to Vault CRM as the key multi-year test.
02 Business model

Subscriptions in a regulated niche

Veeva makes most of its money from subscriptions. Customers pay for access to cloud software and data products over contract terms. In Q1 FY26, subscription services were 84% of total revenue. The rest came from professional services such as setup, training, configuration, and consulting.

The model works because Veeva's tools sit inside important workflows. Customers use them for research, development, quality checks, sales, marketing, and data. In life sciences, these systems often need validation, which means the customer proves the system works in a controlled and compliant way. That makes switching harder.

The same focus also creates risk. Veeva is tied to one industry. If large drug makers slow spending, merge with each other, or move key systems to a rival, Veeva feels it. The top 10 customers made up 28% of total revenue in each of fiscal 2024, 2025, and 2026.

03 Product portfolio

Four clouds, one industry

Growth engine

Veeva Development Cloud

This supports research and development work, including regulated processes before a product reaches the market. It is part of the R&D and Quality Solutions segment, the larger and faster-growing side of the mix.

Growth engine

Veeva Quality Cloud

This helps life sciences companies manage quality processes and compliance. It benefits from the same switching costs that come with validated systems.

Cash cow

Veeva Commercial Cloud

This covers sales and marketing tools, including CRM. The product line is important, but it faces the highest near-term risk because customers are moving from legacy Veeva CRM to Vault CRM.

Steady

Veeva Data Cloud

This provides data products used in commercial work. It sits with Commercial Solutions for reporting and can help deepen customer ties.

Option

Vault CRM

Vault CRM is Veeva's new CRM system built on its own Vault platform. If the migration works, Veeva gains more control over its roadmap and less dependence on Salesforce.

04 Business segments

R&D now leads the mix

Commercial Solutions45%modest
R&D and Quality Solutions55%growing fast

For Q1 FY27, Veeva reported 45% of total revenue from Commercial Solutions and 55% from R&D and Quality Solutions. Customer concentration remains important because the top 10 customers were 28% of total revenue in fiscal 2026.

05 Risk factors

What could break the story

CRM customers leave for Salesforce

High impact · Medium odds

Veeva is moving CRM customers from its legacy Salesforce-based product to Vault CRM. During that window, Salesforce is directly targeting the same customers. Veeva has disclosed that some customers have chosen, or may choose, a competitor.

We watchManagement comments on CRM churn, named large customer losses, and the net revenue impact of Vault CRM wins versus Salesforce losses.

Vault CRM migration slips

High impact · Medium odds

Vault CRM is a strategic move, but large software migrations can run late or cause customer pain. If go-lives are weak, Veeva could lose trust in the commercial business. That would also give Salesforce more time to win accounts.

We watchLarge customer go-live updates, implementation delays, support issues, and any change to the support timeline for legacy Veeva CRM.

R&D growth cannot offset commercial weakness

Medium impact · Medium odds

R&D and Quality Solutions is the key growth engine and was 55% of total revenue in fiscal 2026 and Q1 FY27. The bull case needs that segment to keep outgrowing Commercial Solutions. If it slows while CRM churn rises, total growth could disappoint.

We watchThe quarterly revenue mix, R&D and Quality Solutions growth commentary, and whether management still expects the R&D share to rise.

Large customer concentration

Medium impact · Medium odds

The top 10 customers were 28% of total revenue in fiscal 2026, the same share as in fiscal 2025 and fiscal 2024. Losing one large customer, or seeing major customers merge and reduce systems, could hurt growth. This risk matters more during the CRM transition.

We watchTop 10 customer share, life sciences merger activity, and any disclosure of large account non-renewals.

Sensitive data and compliance failures

High impact · Low odds

Veeva handles software and data used in a complex global regulatory setting. A major data security, privacy, or compliance failure could damage trust. In this market, trust is part of the product.

We watchSecurity incidents, privacy claims, regulatory findings, and higher spending tied to remediation.
06 Quick answers

In one breath

What does Veeva Systems do?

Veeva sells cloud software, data tools, and services to life sciences companies. Its products help with work from research and development through sales and marketing.

Why is Veeva moving away from Salesforce?

Veeva's older CRM product was built on Salesforce's platform. Veeva is moving customers to Vault CRM, its own platform, so it can control the product more directly and reduce dependence on Salesforce.

What is the biggest risk for Veeva stock?

The biggest watch item is CRM churn during the Vault CRM migration. Salesforce is competing for those same customers, and Veeva has disclosed that some customers have chosen competitors.

Which part of Veeva is growing in importance?

R&D and Quality Solutions is now the larger reporting segment. It made up 55% of total revenue in fiscal 2026 and again in Q1 FY27.